Answers are grounded in this paper and cite their sources.
Osteoporotic fractures represent a significant clinical challenge, primarily due to impaired angiogenesis, defective osteogenesis, and the disruption of their functional coupling. However, therapeutic strategies capable of simultaneously restoring both vascular regeneration and bone formation in osteoporotic bone remain elusive. Remote ischemic preconditioning (RIPC) has been demonstrated to be a non-invasive therapeutic strategy that stabilizes hypoxia-inducible factor-1α (HIF-1α) through the induction of a mild hypoxic microenvironment, thereby upregulating multiple angiogenic factors and promoting tissue repair, but its role and molecular mechanism in osteoporotic fracture repair remain unclear. In this study, we show that RIPC accelerates the healing of osteoporotic fractures in mice by enhancing both angiogenesis and osteogenesis. Proteomic profiling of fracture callus tissues revealed upregulation of SIRT6 expression and robust activation of the SIRT6–HIF-1α signaling axis. Endothelial-specific deletion of SIRT6 abolishes the pro-regenerative effects of RIPC. Mechanistically, under hypoxic conditions, endothelial progenitor cell-derived SIRT6 deacetylates and stabilizes HIF-1α, thereby promoting the secretion of NOGGIN3 and MMP9 and augmenting osteoblast-mediated bone formation. In turn, osteoblast-derived SLIT3 and VEGF drive endothelial differentiation toward the H-type phenotype, establishing a positive feedback loop that tightly couples angiogenesis with osteogenesis. To translate these findings into a therapeutic application, we developed bone-targeted nanoparticles encapsulating MDL-800, a selective SIRT6 activator, which enhances bone-specific delivery, effectively activates the SIRT6–HIF-1α pathway, and restores angiogenic–osteogenic coupling both in vitro and in vivo . Collectively, our findings identify the endothelial SIRT6–HIF-1α axis as a central regulator of RIPC-induced angiogenic–osteogenic crosstalk, offering a promising, mechanism-based therapeutic strategy for treating osteoporotic fractures.
No takes yet. Share an insight, caveat, or question.
李小群 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: